The study developed a dynamic tuberculosis model for India that includes the early stages of the disease: non-infectious, infectious asymptomatic and infectious symptomatic. The scenarios assumed 50% vaccine efficacy over 10 years preventing progression to infectious symptomatic disease, any infectious disease, or any disease. After 3 years, the difference in the proportion of cumulative episodes of symptomatic disease averted was small (1.6%, 2.3% and 2.3%, respectively). After 20 years, vaccines against only symptomatic disease averted significantly fewer cases (7.3%) than those against any infectious (19.4%) or disease (23.3%), by preventing transmission from the asymptomatic stage. The impact of new vaccines on the population depends on their effectiveness against infectious asymptomatic tuberculosis. The study recommends analysis of sputum samples in vaccine trials to better estimate efficacy against asymptomatic disease. A key limitation is the uncertainty of the model inputs, which requires further data collection on the transmission of asymptomatic disease.